Patents by Inventor Lea Aurelie BOUCHE

Lea Aurelie BOUCHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Covalent PPARG inverse-agonists
    Publication number: 20240150277
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: May 9, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Knut EIS, Timo STELLFELD, Léa Aurelie BOUCHÉ, Elisabeth POOK, Joseph Peter BLUCK, Philip LIENAU, Constantia PANTELIDOU, Isabel Sophie JERCHEL-FURAU, Ulf BRÜEGGEMEIER, Sven CHRISTIAN, Detlev SÜLZLE, Anders Roland FRIBERG, Simon HOLTON, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Douglas ORSI, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE
  • NOVEL COMPOUNDS
    Publication number: 20240132471
    Abstract: The invention relates to novel compounds having the general formula Ib wherein R1, R2, R1, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 25, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lea Aurelie BOUCHE, Wolfgang GUBA, Georg JAESCHKE, Stefanie Katharina MESCH, Angélique PATINY-ADAM, Christian SCHNIDER, Sandra STEINER, Andreas Michael TOSSTORFF
  • PYRIMIDINEDIONE DERIVATIVES
    Publication number: 20220411381
    Abstract: The present invention covers pyrimidinedione derivatives of general formula (I): (I), in which R1, R2, R4, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 29, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Lea Aurelie BOUCHE, Stefan KAULFUSS, Katja ZIMMERMANN, Hartmut REHWINKEL, Roland NEUHAUS, Roman HILLIG, Duy NGUYEN, Judith GÜNTHER, Adelaide Clara FARIA ALVARES DE LEMOS
  • ACYL SULFONAMIDES FOR TREATING CANCER
    Publication number: 20220226279
    Abstract: The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6? Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.
    Type: Application
    Filed: April 20, 2020
    Publication date: July 21, 2022
    Inventors: Léa Aurelie Bouché, Daniel Korr, Antonius ter Laak, Ernesto Amaury Fernandez-Montalvan, Naomi Barak, Roman Hillig, Roland Neuhaus, Matyas Gorjanacz, Vera Pütter, Stefan Niklaus Gradl, Simon Anthony Herbert, Steven James Ferrara, Craig Strathdee, Jacob Jaffe
  • THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS
    Publication number: 20200123147
    Abstract: The present invention provides PRMT5 inhibiting compounds of general formula (I): A compound of general formula (I), in which R1, R2, R3 R4, R5, R6, R7 L1 and L2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: June 21, 2018
    Publication date: April 23, 2020
    Inventors: Lea Aurelie BOUCHE, Duy NGUYEN, Daniel KORR, Marcus KOPPITZ, Antonius TER LAAK, Amaury Ernesto FERNANDEZ-MONTALVAN, Thi Thanh Uyen NGUYEN, Stefan PRECHTL, Andreas JANZER